Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 309.79 | 318.63 | 351.81 | 267.37 | 263.06 |
Total Expenses | 299.94 | 304.39 | 331.77 | 247.81 | 248.39 |
Profit Before Tax | 9.85 | 16.59 | 32.73 | 19.57 | 14.67 |
Profit After Tax | 6.33 | 11.38 | 25.30 | 13.56 | 10.18 |
Operating Profit after Depreciation | 20 | 21.04 | 26.21 | 24.10 | 19.81 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 223.34 | 228.36 | 142.03 | 129.78 | 124.13 |
Total Non Current Assets | 235.25 | 235.77 | 200.73 | 176.01 | 145.61 |
Total Current Assets | 155.27 | 159.12 | 156.02 | 126.29 | 107.22 |
TOTAL ASSETS | 390.52 | 394.89 | 356.75 | 302.30 | 252.83 |
Total Shareholder's Fund | 176.81 | 168.61 | 152.23 | 129.22 | 115.73 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 24.31 | 14.70 | -11.24 | 35.17 | 14.55 |
Net Cash used in Investing Activities | -18.45 | -31.29 | -7.14 | -26.23 | -27.02 |
Net Cash used in Financing Activities | -6.56 | 16.89 | 10.83 | -2.55 | 12.45 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 303.84 | 318.12 | 347.16 | 261.59 | 258.81 |
Total Expenses | 284.73 | 302.10 | 326.88 | 242.23 | 245.47 |
Profit Before Tax | 19.11 | 18.37 | 32.98 | 19.35 | 13.34 |
Profit After Tax | 13.07 | 13.22 | 25.38 | 13.17 | 9.15 |
Operating Profit after Depreciation | 28.01 | 21.12 | 24.91 | 23.85 | 18.43 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 138.23 | 139.61 | 98.72 | 100.83 | 94.50 |
Total Non Current Assets | 172.88 | 169.80 | 149.68 | 136.32 | 127.74 |
Total Current Assets | 174.49 | 167.59 | 162.32 | 135.43 | 101.21 |
TOTAL ASSETS | 347.38 | 337.39 | 312 | 271.74 | 228.95 |
Total Shareholder's Fund | 176.23 | 164.03 | 151.21 | 126.34 | 113.26 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 14.75 | 4.58 | -14.66 | 21.62 | 13.95 |
Net Cash used in Investing Activities | -13.75 | -27.96 | -7.49 | -5.94 | -13.28 |
Net Cash used in Financing Activities | -0.82 | 22.59 | 14.63 | -7.87 | -2.05 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 78.46 | 92.55 | 89.99 | 72.05 | 69.26 |
Total Expenses | 69.90 | 76.26 | 78.63 | 62.76 | 61.34 |
Profit Before Tax | 4.70 | 10.65 | 7.10 | 3.80 | 1.65 |
Profit After Tax | 3.30 | 7.10 | 6.47 | 4.12 | -0.44 |
Operating Profit after Depreciation | 10.60 | 16.73 | 13.72 | 9.87 | 8.19 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 78.50 | 86.57 | 86.37 | 71.23 | 67.84 |
Total Expenses | 66.70 | 72.80 | 75.56 | 62.20 | 58.37 |
Profit Before Tax | 8.57 | 9.54 | 7.91 | 5.08 | 4.77 |
Profit After Tax | 6.01 | 6.46 | 5.93 | 3.31 | 3.12 |
Operating Profit after Depreciation | 13.06 | 14.20 | 13.09 | 9.67 | 9.80 |
₹1.5/Share
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
SMS Lifesciences India Ltd | ₹1,250 | ₹377.91 |
Sun Pharmaceuticals Industries Ltd | ₹1,745.25 | ₹4,18,743.94 |
Divis Laboratories Ltd | ₹5,733.60 | ₹1,52,209.07 |
Cipla Ltd | ₹1,458.15 | ₹1,17,762.24 |
Torrent Pharmaceuticals Ltd | ₹3,357.15 | ₹1,13,616.11 |
Mankind Pharma Ltd | ₹2,488.40 | ₹1,02,663.15 |
09 Nov 2024, 12:30 pm
20 Aug 2024, 04:03 pm
08 Aug 2024, 05:18 pm
28 May 2024, 12:15 pm
28 May 2024, 10:59 am